NOVARTIS
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
An Open, Randomized Pilot Study to Evaluate the Use of Basiliximab With an Optimized Cyclosporine Dosing on Renal Function in "de Novo" Liver Transplantation.
Phase 4
Completed
- Conditions
- Liver Transplantation
- First Posted Date
- 2006-06-22
- Last Posted Date
- 2010-08-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 48
- Registration Number
- NCT00343226
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
Phase 3
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2006-06-21
- Last Posted Date
- 2017-09-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1292
- Registration Number
- NCT00340834
- Locations
- 🇺🇸
Associated Neurologists, PC, 69 Sand Pit Road, Suite 300, Danbury, Connecticut, United States
🇺🇸AMO Corporation, Tallahassee, Florida, United States
🇺🇸Neurological Associates, Pompano Beach, Florida, United States
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older
Phase 2
Withdrawn
- Conditions
- Influenza
- First Posted Date
- 2006-06-21
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Novartis
- Registration Number
- NCT00342940
- Locations
- 🇬🇧
Chiltern International Limited , Chiltern Place, Upton Road, Slough, United Kingdom
Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 362
- Registration Number
- NCT00338936
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
- Conditions
- Neoplasms, Breast
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- Novartis
- Registration Number
- NCT00338247
- Locations
- 🇬🇧
Novartis Investigative Site, Shrewsbury, United Kingdom
Efficacy and Safety of Lumiracoxib 400 mg in Arthroscopic Knee Surgery
Phase 4
Completed
- Conditions
- Pain
- First Posted Date
- 2006-06-05
- Last Posted Date
- 2007-12-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 110
- Registration Number
- NCT00333567
- Locations
- 🇩🇪
Novartis, Nuernberg, Germany
Comparative Study of Valsartan and Amlodipine Versus Amlodipine Alone in Hypertension
Phase 4
Completed
- Conditions
- Hypertension
- First Posted Date
- 2006-06-05
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 551
- Registration Number
- NCT00333489
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 281
- Registration Number
- NCT00333138
- Locations
- 🇬🇧
Novartis Investigational site, Newcastle upon Tyne, United Kingdom
Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
Phase 3
Completed
- Conditions
- OsteoporosisPostmenopausal
- Interventions
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2011-11-16
- Lead Sponsor
- Novartis
- Target Recruit Count
- 83
- Registration Number
- NCT00332709
- Locations
- 🇩🇪
Novaertis Investigative Site, Hamein, Germany
🇩🇪Novartis Investigative Site, Witten, Germany
Letrozole in Metastatic Breast Cancer in Combination With Chemotherapy
Phase 2
Completed
- Conditions
- Metastatic Breast Cancer
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 24
- Registration Number
- NCT00333047
© Copyright 2025. All Rights Reserved by MedPath